[1] WANG S, SHEN L, LUO H.Identification and validation of key miRNAs and a MicroRNA-mRNA regulatory network associated with ulcerative colitis[J]. DNA Cell Biol, 2020, 40(2):147. [2] 陈莉娟,李彦龙,杨维建,等.基于NLRP3/Caspase-1通路探讨薏苡仁多糖对溃疡性结肠炎体外炎症模型的干预作用及机制[J].重庆医科大学学报,2023,48(11):1323-1330. [3] ZAITSU J, KURAOKA K, ISHIKAWA A, et al.Intramucosal poorly differentiated adenocarcinomas detected in a patient with long-standing ulcerative colitis[J]. Case Rep Oncol,2020,13(3):1176-1184. [4] 李彦龙,任彦彦,常利军,等.薏苡仁多糖对溃疡性结肠炎小鼠Caspase-1介导细胞焦亡通路的影响[J].时珍国医国药杂志,2022,33(11):2633-2636. [5] MUNKHOLM P.Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease[J].Alimentary Pharmacology & Therapeutics, 2003, 18: 1. [6] Mathurin Fumery,Parambir S.Dulai,et al. Risk factors, and outcomes of colorectal cancer in patients with ulcerative colitis with low-grade dysplasia: A systematic review and meta-analysis[J]. Clinical Gastroenterology and Hepatology, 2017, 15(5): 665. [7] LAUGESEN K B, TØTTRUP A. Kolorektal cancer ved colitis ulcerosa [Colorectal cancer in ulcerative colitis][J]. Ugeskr Laeger, 2014, 176(4A): V07130441. [8] 李宝瑜,李彦龙,田旭东.中药防治溃疡性结肠炎相关机制的研究进展[J].中医药导报,2023,29(5):212-216. [9] GUO X Y, LIU X J, HAO J Y.Gut microbiota in ulcerative colitis: Insights on pathogenesis and treatment[J]. J Dig Dis, 2020, 21(3): 147-159. [10] 黄水兰,张磊昌,高强强,等.中医药防治溃疡性结肠炎机制研究进展[J].辽宁中医杂志,2024,51(7):206-212. [11] 李翠,张聪伟,刘力,等.基于“本体虚弱,湿瘀毒蕴”论治溃疡性结肠炎[J].河北中医,2024,46(7):1190-1193. [12] 中国中西医结合学会.溃疡性结肠炎中西医结合诊疗指南[J].中国中西医结合杂志,2024:1-7. |